



16th Annual Summer Social With Lightning Pitches

Keynote

Kenneth Kim, Senior Economist, KPMG LLP



Executive Roundtable, MORSE – Third Wednesday of the Month

Sep 3 Angel and Family Office Investing in Healthcare

John Hession, Moderator

John Hallinan

John Parker, Springhood Ventures & Charles Hood Foundation

Josko Silobrcic, Hub Angels

Oct 5 AI – Productivity Improvements and Implementation

Oct 27 Inaugural NorthEast Healthcare Executive Network NYC

Nov 2 Directors and Officers

Dec 7 Year in Review: IPO, M&A, PE & Venture




Idea. Innovation. Transformation.



Optimizing your marketing for **better business outcomes.**

Strategically guiding your [website](#), [social channels](#), [paid ads](#), and [customer journey](#) to work together for an **integrated, full funnel approach.**



Real week-by-week improvements Cicada brought for their medtech client in the first 6 months ^

Foley Hoag's Healthcare Practice

Industry Subsectors



Healthcare
Services



Hospitals /
Academic
Institutions



Medical
Devices
& Equipment



HCIT &
Digital
Health



Payors



PE, VC &
Angel
Investing

Regulatory/Government Strategies

Our nationally recognized team brings significant experience from within the FDA, senior-level positions in Cabinet departments, Capitol Hill, regulatory agencies, trade associations, private industry & patient advocacy groups

Healthcare Litigation

From kickbacks, overpayments, or billing and coding problems to challenges to laws and regulations or payor-provider agreement disputes, we can help you develop effective legal strategies while minimizing your risk

Corporate Advice & Transactions

From formation and financings to M&A and public offerings, we help clients throughout their life cycle make informed decisions, improve performance and plan for successful exits

Intellectual Property

With a deep understanding of technology and science combined with proven legal expertise in IP business law, we successfully develop and manage intellectual property to help clients achieve their business goals



Colin J. Zick

**PARTNER, CO-CHAIR,
HEALTHCARE PRACTICE, PRIVACY,
AND DATA SECURITY PRACTICE,
AND COVID-19 TASKFORCE**

[617.832.1275](tel:617.832.1275)

czick@foleyhoag.com



Innovation is in your DNA. It's in ours, too.

At Alira Health, our mission is to enable healthcare transformation.

We complement your expertise with a full spectrum of advisory services to uncover opportunity, accelerate innovation, and improve outcomes for patients around the world.

PRACTICE AREAS

PRODUCT
DEVELOPMENT
LAB

CLINICAL

REGULATORY

MARKET
ACCESS

STRATEGY
CONSULTING

TRANSACTION
ADVISORY



www.alirahealth.com

Paragon Medical

AMETEK®

Paragon Medical offers diverse manufacturing capabilities that are uniquely equipped to serve markets spanning electrophysiology, cardiac rhythm management, neuromodulation, orthopedics, robotics, minimally invasive surgery, drug delivery, and many others.

We offer over 1.2 million square feet of operating space powered by over 2,700 team members. Our collaborative, multi-site approach gives you access to a range of design services, manufacturing capabilities, and project management, enabling you to commercialize with excellence.



Precision Metal
Components



Nitinol & Precision
Tube Cutting



Plastic Injection
Molding



Laser Processing &
Wire Assemblies



Medical Interconnects
& Cables



Clean Room
Assembly Expertise

Delivering the *right* software solutions to yield optimal business outcomes



Firmware & Embedded
Systems Development



Application
Development



GUI Development



Mobile Development
(Android & iOS)



Web Application
Development



Cloud & Enterprise
Technologies

500+

Completed
Projects

100+

Software
Engineers

15+

Average Years
Experience

90+%

Repeat
Business Rate



The
**Baldwin
Group**

Insurance Brokerage & Consulting Firm

Dan Giampietro

Senior Advisor

Dan.Giampietro@baldwin.com

Office: 781.202.9138

Cell: 203.892.0070

4,000 + professionals

2 million corporate clients

Licensed in all 50 states

& access to all insurance carriers

Life Science-Tailored Coverages:

- Intellectual Property Protection
- Supply Chain Risk Management
- Mergers & Acquisition Risk Management
- Clinical Trial/Product Liability
- Global Program Implementation
- Executive & Management Liability
- Employee Benefits
- General Liability
- Cyber Coverage
- IPO Coverage
- Professional Liability
- Worker's Compensation
- Life Science Specific Property Coverage



Transactional Experience

Morse represented its clients in a range of **venture capital** deals in 2021, including convertible note financings and equity investments. Our attorneys closed 75 venture financings totaling nearly \$1.4 billion in proceeds raised.

Life Sciences Focus

Morse represents biotechnology, pharmaceutical and medical device companies, institutions, and investors in a wide range of sophisticated legal matters that arise in connection with the development, protection, and commercialization of their diagnostic and therapeutic solutions.

Our **life sciences** professionals are experienced in counseling clients in areas such as:

- Corporate finance, governance, and mergers and acquisitions
- Intellectual property
- Licensing and strategic alliances
- Employment, executive compensation, and employee benefits



Dan Blanchard
Member and Corporate Dept. Chair

dblanchard@morse.law
781-697-2216



Delivering value across the business life cycle

CrossCountry works with Life Science and Healthcare companies to help them achieve goals related to improving accounting and finance operations, managing spend and cash needs, software selection and implementation, assessing public company readiness, and managing the transaction process.

Start-ups & Private Companies • IPO / Pre-IPO • Public Companies



Jen Cadigan-McGoldrick
Partner

jcadigan@crosscountry-consulting.com



A leading provider of specialized finance, operations, and technology advisory services.



www.crosscountry-consulting.com



Rolling a boulder uphill: Structural change watchlist

Uncertainty hangs like a fog.


Kenneth Kim, CFA, CBE
Senior Economist

August 3, 2026



Oil swings back higher


Crude Oil Price



Source: KPMG Economics, EIA, CME (July 29, 2026), Haver Analytics

Inflation elevated due to energy prices


Inflation



Source: KPMG Economics, BLS (June 2026), BEA (June 2026), Haver Analytics

Car insurance +49%, eating out +40%, CPI +28%

Inflation since COVID




Source: KPMG Economics, Bureau of Labor Statistics (June 2026), Haver Analytics



© 2026 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

Fed late to raise rates during COVID, what now?


Inflation and Rates



Source: KPMG Economics, FRBNY (June 2026), BEA (June 2026), Haver Analytics

Bond market signaling higher rates

Interest Rates



Source: KPMG Economics, FRBNY, US Treasury (July 30, 2026), Haver Analytics




02

Consumer and financial markets

US equities lose risk appetite

US Equities, Treasuries, Dollar




Source: KPMG Economics, SP, TPI, WSJ (July 29, 2026), Haver Analytics

High income households power consumer spending

Personal Outlays By Income Group


Index, Q4-2019=100



Source: Moody's Analytics

Consumer confidence dropped to record low

Consumer Sentiment



Source: KPMG Economics, University of Michigan (July 2026), Haver Analytics




03

Health care sector

Life expectancy hits new high of 79 years

US Life Expectancy




Source: KPMG Economics, NCHS, Haver Analytics



© 2026 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

Health care employment adds workers

Health Care vs Tech Employment



Source: KPMG Economics, BLS (June 2026), Haver Analytics



© 2026 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

Most exposed to AI

Occupation Group	Exposure to AI Automation (% of tasks)		
		Life, Physical, and Social Science Occupations	31.0
		Educational Instruction and Library Occupations	29.5
Office and Administrative Support Occupations	75.5	Community and Social Service Occupations	27.5
Business and Financial Operations Occupations	68.4	Healthcare Practitioners and Technical Occupations	23.1
Computer and Mathematical Occupations	62.6	Protective Service Occupations	20.7
Sales and Related Occupations	60.1	Transportation and Material Moving Occupations	20.0
Management Occupations	49.9	Food Preparation and Serving Related Occupations	18.1
Legal Occupations	47.5	Personal Care and Service Occupations	17.5
Arts, Design, Entertainment, Sports, and Media Occupations	45.8	Healthcare Support Occupations	15.5
Architecture and Engineering Occupations	40.7	Production Occupations	14.4


Source: PWBM, The Projected Impact of Generative AI on Future Productivity Growth (September 8, 2025)



© 2026 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

Supply of immigrant workers plummets

Net International Migration



Source: KPMG Economics, Census Bureau, Haver Analytics




04


The future and longer term

Gen AI adoption compared to past tech

At Work




Outside of Work



Source: PWBM, The Projected Impact of Generative AI on Future Productivity Growth (September 8, 2025)

Insatiable AI demand powers construction


Construction for Data Centers and Electric Plants



Source: KPMG Economics, Census Bureau (May 2026), Haver Analytics

AI-linked tech spending 1/3 of all capex

AI-Related Tech Spending




Source: KPMG Economics, BEA (Q1 2026), Haver Analytics

Economic growth continues in 2026

GDP and Components

Contributions to real GDP, SAAR %



Source: KPMG Economics, Bureau of Economic Analysis




© 2026 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

Population slows due to lower fertility

Population growth of the United States

Percent contribution



Source: KPMG Economics, Congressional Budget Office




© 2026 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

Need AI, quantum, health care, space economy to be key

Real and Potential GDP Growth

Annual - % Change, Decade Averages




Source: KPMG Economics, BEA, CBO, Haver Analytics



© 2026 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP391414-1A

The alternative...

Real GDP: Japan 0.6%, US 2.5% (2015-25 avg)



Source: KPMG Economics, BEA, CAO (Q1 2026), Haver Analytics



Some or all of the services described herein may not be permissible for KPMG audit clients and their affiliates or related entities.



kpmg.com/socialmedia

The information contained herein is of a general nature and is not intended to address the circumstances of any particular individual or entity. Although we endeavor to provide accurate and timely information, there can be no guarantee that such information is accurate as of the date it is received or that it will continue to be accurate in the future. No one should act upon such information without appropriate professional advice after a thorough examination of the particular situation.

© 2026 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.



LIGHTNING PITCHES!



Lightning Pitch **Companies**

[1612Bio](#) **Kamran Rizzolo**, Founder & CEO krizzolo@1612bio.com

[Alpha Cure Therapeutics](#) **Scott Cohen**, CEO scottcohen@alphacuretx.com

[AltrixBio](#) **David Pass**, CEO davidpass@altrixbio.com

[AsparaGlue](#) **Paul Birkmeyer**, CEO pbirkmeyer@asparaglu.com

[CPR Therapeutics](#) **Norman Paradis**, CEO norman@cprtherapeutics.com

Entero Devices **Rob Mulligan**, Business & IP Strategy rmulligan@starsidecap.com

[EpiWatch](#) **Teresa Prego**, CEO tprego@epiwatch.com

[EyeJets](#) **David Potter**, Advisor dpotter@sagepartners.net

[Eyevara](#) **Dr. Rae Huang**, OD MS IACMM, CEO drhuang@outlook.com

[FlexiGrace Bio](#) **Arun Singh**, CEO & Founder arun.singh@flexigrace.bio

[GMB Solutions](#) **Daniel Schoener**, CEO daniel@greenmountainbiotechsolutions.com

[Highland Instruments](#) **Alex Herzlinger**, CBO alex@highlandinstruments.com

[Jeevan Therapeutics](#) **Terrence West**, CEO terrencew@jeevantx.com

[Lenneuro](#) **Steven Scherr**, CTO steve@lenneuro.com

[MotiveTx](#) **Russ Ernst**, Co-Founder & CEO russ@motivetherapeutics.bio

[MyEyesAI](#) **Rohit Mahajan**, CEO rohit@myeyesai.com

[Navia Medical](#) **Sean Kyne**, Founder & CEO sean@naviamed.com

[Neurofine](#) **Christopher Lear**, Chief Strategy Officer chris@neurofine.com

[Nuroflux](#) **David Cardoso**, Co-Founder & CBO david.cardoso@nuroflux.com

[Parasail](#) **Dustin Armstrong**, President dustin.armstrong@parasailllc.com

[Progress Health Systems](#) **Alan Forbes**, Co-Founder, CEO Alan@Progresshealthsystems.com

[Prometheus Therapeutics](#) **Ajay Wakhloo**, CEO ajay@prometheustherapeutics.com

[SLBST Pharma](#) **Mark Connell**, Co-Founder & CEO mark.connell@slbstpharma.com

[Spheric Bio](#) **Connor Verheyen**, Co-Founder & CEO connor@sphericbio.com

[SpotOnMe](#) **Rodrigo Navarro**, COO rodrigo@spotonmenow.com


Tetraxis Therapeutics **Liam Casey**, CEO liam.casey@tufts.edu

[WeDaita](#) **Wenliang Zhang**, Founder & CEO wenliang.zhang@wedaita.com

[WellSole](#) **Ted Finn**, Founder ted@iws4u.com

[Wicked Technologies](#) **Alli Truttmann**, Founder & CEO alli@wickedsheets.com

[Zephyr Apnea](#) **Theresa Mock**, COO terri@zephyrapnea.com



PROUD SPONSOR

Simbex

We enable innovators to successfully bring medical device and consumer health products to market through premier engineering and strategic consulting

Engineering

Mechanical, electrical, firmware, software, algorithms, and transfer to manufacturing.

Commercialization

Regulatory and reimbursement strategy, market assessment, primary research, quality systems.

Partnership

Working alongside startups, scaling companies and strategic enterprises since 2000.


Simbex.com

Lebanon, New Hampshire

ISO-13485 certified




How do we force self-destruction?



Why are we different?

- ✓ **Derisked approach:** 2025 FDA approved drug ONC201
- 1612C can be used for **much broader** types of cancers
- 1612C targets only ClpP and **reduces side-effects**


Progress to date



Roadmap to clinic



Who we are



Pioneered protease agonism for cancer
25+ years drug discovery experience




UNIVERSITY OF
TORONTO



BROAD
INSTITUTE



Alpha Cure
THERAPEUTICS



Unlocking high value **intracellular** targets p53, PI3K α , KRAS,
combining pathway inhibition with
localized **beam activated α -particles**

Oral small molecule cancer drugs

Patients - biomarker driver mutations

Breast, Lung, more

Bi-modal

Clinically Validated



**No Radioactive Decay/Supply Chain
or Toxicity**

**Raising Seed
\$2.5M for DC**

- In vivo efficacy
- PK/PD
- Tox

scottcohen@alphacuretx.com



SEED: \$2M

SAFE post-money val cap \$6M
or CN option, **\$145K closed**

Pre-Seed: \$333K

(\$100K non-dil, \$33K co-founder)

Use of Seed Funds

- Sterilization feasibility
- Confirm regulatory status with FDA
- Lung POC incl. large animal study

Growing IP Portfolio

3 issued US utility patents

Publications

Science - 2024

J. Am. Chem. Soc. - 2025


pbirkmeyer@asparglue.com

AsparaGlue


REVOLUTIONIZING BIOSURGERY
with an elastic “superglue”

\$10B: Sealants, Adhesives, Hemostats

SUPERIOR STRENGTH



SEALANT COMPETITION



Berkeley
LSEC

Venture
Grant
Awardee



Paul Birkmeyer
CEO



Dr. Tom Jozellak
CSO
(Interim)



Prof. Phil Messersmith
Co-Founder



Dr. Subhajit Pal
Co-Founder



Dr. Jeffrey Velotta
Thoracic Surgeon



Shella Hemeon-Heyer
Regulatory Advisor

ENTERO DEVICES

Designing new endoscopy tools that impact the quality and cost of healthcare

MARKET STRAIN & OPPORTUNITY

~15M

Annual U.S. Colonoscopy Procedures

- **Screening Demand:**
CDC guidance driving rapid colorectal cancer screening growth
- **Financial Squeeze:**
Average colonoscopy reimbursement is ~\$1,100 while typical endoclip costs ~\$150 (multiple used per closure).
- **Key Issue:**
Hospital capacity and high clip costs severely strain clinical margins.


FIRST PROJECT: HEMOSTATIC ENDOCLIP

~\$90M TAM

3 U.S. Incumbents Lagging in Innovation

*Imaginative engineering meets
design-for-manufacturing*

A lower-cost, higher-performing hemostatic clip designed to reliably control bleeding following polyp or tissue removal.



✓ **Largest Opening**
Improves tissue capture confidence

✓ **Shortest Tail**
Reduces interference in lumen

✓ **Minimal Parts**
Simplified mechanical design

✓ **Lowest Cost**
Fulfills hospital economic goals

LEADERSHIP & EXECUTION



Rob Mulligan, MBA
Business and IP Strategy



Brendan LaBrecque
Design and Engineering

SEEKING PARTNERSHIPS & INVESTMENT

- **Funding:**
Seed round to advance our hemostatic clip through DFM.
- **Clinical Network:**
G.I. Dr.'s for clinical feedback and voice-of-customer input.
- **Strategic Connections:**
Relationships with established G.I. medtech leaders.

CONTACT

 rmulligan@starsidecap.com

EpiWatch Continuous Seizure Monitoring For 3.5 Million in US with Epilepsy



EpiWatch®

FDA-cleared tonic-clonic seizure detection and alerting

Low false alarm rate
FSA/HSA eligible



FDA CLEARED

Ages 5+ Works with Apple Watch For Your Kids


Automatically alerts caregivers when a tonic-clonic seizure is detected



Subscription model: \$19.99/month

Clinically validated with low false alarm rate

FDA 510(k) cleared for ages 5 +




Detect

Seizure detection, alerting, monitoring on easily wearable non-stigmatizing Apple Watch, with additional manual alerting capability




Alert

Rapidly alerts caregiver network and allows rapid access to on-demand therapy



Monitor

Passive monitoring and seizure detection data enhances accurate seizure summary info



Dashboard

March 2026

Seizures Auras False Pos Unclass Not Sure

Timeline To Classify

Wednesday, March 4

EVENT Generalized Tonic-Clonic 3:58 PM

Report Preview

EpiWatch Seizure Report

Dec 25, 2025 - Mar 26, 2026

Generated: Mar 25, 2026 at 12:28 PM

Summary Statistics

7	8
Total Confirmed Seizures	Total Auras

Seizure Type Breakdown

Seizure Type	Count
Generalized Tonic-Clonic	2
Absence	2
Partial to Bilateral Tonic-Clonic	1

Monthly Trend

Month	Seizures	Auras	False Pos.	Not Sure
Dec 2025	0	0	0	0
Jan 2026	1	0	0	0
Feb 2026	0	0	0	0
Mar 2026	0	1	0	0


Event Log

Date/Time	Type	Seizure Type	Duration	Severity	Notes
Dec 25, 5:13 PM	Aura	—	—	—	—
Dec 25, 5:15 PM	Aura	—	—	—	—
Jan 10, 2:18 PM	Aura	—	—	—	—
Jan 10, 2:14 PM	Aura	—	—	—	—
Jan 10, 4:27 PM	Aura	Partial to Bilateral Tonic-Clonic	—	—	—
Jan 10, 4:45 PM	Aura	—	—	—	—
Jan 20, 10:20 PM	Aura	—	—	—	—
Jan 20, 4:14 PM	Aura	—	—	—	—
Mar 2, 6:20 PM	Aura	Absence	—	—	—
Mar 2, 6:40 PM	Aura	Generalized Tonic-Clonic	—	—	—



PREDICTIVE GLUCOSE THROUGH THE EYE.

The world's first continuous, predictive and non-invasive glucose monitoring platform, measuring blood **through the retina**.



Direct measurement
from **retinal blood vessels**
where blood is
directly visible.



DIRECT BLOOD MEASUREMENT

Through retinal
blood vessels



CONTINUOUS

Real-time
glucose monitoring



PREDICTIVE

AI-powered
glucose prediction



NEEDLE-FREE

No sensor. No patch.
No pain.



CLINICAL VALIDATION WITH



Clinical study underway
led by

Prof. Nicolas Musi, MD, PhD
Director of Endocrinology & Diabetes

SERIES A

\$10M

RAISING NOW

To complete clinical validation,
advance **FDA** pathway and
launch with **strategic partners**.



**CLINICAL
VALIDATION**
with leading
medical centers



**FDA 510(k)
PATHWAY**
for regulatory
clearance



**COMMERCIAL
LAUNCH**
through strategic
partnerships

CONTINUOUS. PREDICTIVE. NON-INVASIVE. | TRANSFORMING DIABETES CARE. SAVING LIVES.


Eyevara Reform™

Building the Invisalign of vision

Dr. Rae Huang — OD, MS, IACMM

Founder, Inventor & CEO

drhuang@eyevara.com, (781) 301 1436



Orthokeratology (Ortho-K) —
hard contact lenses to reshape
corneas

BREAKTHROUGH

Eyevara Reform™ patented
novel lens design lands on the
sclera — more comfortable

Myopia **NOT** just blurry vision — progressive eye disease with serious risk

-> **30% of North Americans are now myopic, 50% in 2050**

THE MARKET
\$550m

**15% CAGR — adding adults could
double market**

**Clear FDA 510(k) 1H 2027
→ launch 2H 2027**



Green Mountain Biotech Solutions

On-shoring and decarbonizing the manufacturing of critical drug intermediates

PRE-SEED
Raising \$700K

THE PROBLEM

Pharma **emits** more carbon than the automotive sector and 80% of its **supply chain** originates from risky global sources.

THE MARKET

\$3.5B GLP-1 peptide beachhead (**53% CAGR**) inside a **\$200B** microbially-fermented biologics market.

THE SOLUTION

A **phototroph + heterotroph consortium** turns light and CO₂ into therapeutic peptide intermediates.

THE COMPARISON

		Emissions
Traditional Fermentation	Agricultural feedstock → sugar → yeast fermentation — carbon-heavy, land-intensive, >94% of emissions in raw materials	5,000
Chemical Synthesis (SPSS)	Resin-based synthesis with hazardous solvents (e.g., DMF, DCM) — 15-20 tons of solvents for 1 kg of peptide	100,000
Green Mountain Biotech Solutions	Light + CO ₂ → phototroph + heterotroph consortium — built on existing fermentation infrastructure	500

kg CO₂ / kg peptide


THE TRIPLE ADVANTAGE

20-30%
lower cost of goods

94%
lower carbon footprint

100%
supply chain control

THE PROCESS



THE TEAM

Daniel Schoener, CEO daniel@greenmountainbiotechsolutions.com
Kevin Litcofsky, Advisor (Presenting) kevin@litcofsky.net

Advisory team of 6 PhDs with 10+ patents. Experience across microbiology, fermentation development, biomanufacturing, and market analysis.

Highland Instruments

A NEUROTECHNOLOGY COMPANY

- ✓ 500K moderate PD patients face a treatment gap
- ✓ 4 ESStim™ clinical studies → significant improvements in PD motor symptoms
- ✓ Series A to fund pivotal study for 2029 launch



NEHEN

August 2026

Alex Herzlinger – CBO

alex@highlandinstruments.com

NOURISHING HOPE TARGETING WHAT MATTERS



JEEVAN
THERAPEUTICS

Using a VHH scaffold, our bispecific nanobody is designed to target cells that promote inflammation and flares.



ENGINEER

We engineered our bispecific nanobody for Crohn's using a VHH scaffold.



DELIVER

Nanobodies travel through the body via the bloodstream and reach the gut.



PENETRATE & TARGET

Nanobodies penetrate the inflamed gut tissue and bind to key targets involved in driving inflammation.



BLOCK & DEplete

Our bispecific nanobodies block trafficking of pathogenic immune cells and deplete those already in the gut, helping to reduce inflammation at the source.

Terrence West
CEO & Co-Founder

Dinesh Chimmanamada
CSO & Co-Founder

Theresa O'Keefe, PhD
Scientific Advisory
Board Member

Mehmet Ozturk, PhD
Scientific Advisory
Board Member



BUILT ON SCIENCE. ROOTED IN PURPOSE.

Innovating Crohn's disease treatments from the ground up



PRECISELY TARGETED

Designed to engage key drivers of inflammation in Crohn's disease with high specificity.



REDUCE INFLAMMATORY SIGNALS

Helps block the signals and cell interactions that fuel chronic inflammation.



DEplete PATHOGENIC CELLS

Targets and helps eliminate pathogenic immune cells already present in the gut.



IMPROVE OUTCOMES

By addressing the underlying drivers of disease, we aim to improve long-term outcomes and quality of life.



OUR MISSION

Develop transformative therapies that improve the lives of people living with Crohn's disease.



CURRENT TRACTION

- Proprietary bispecific nanobody discovery program advancing
- Functional binders identified against both therapeutic targets
- Three provisional patent applications filed
- Bispecific engineering and lead optimization underway



OUR TEAM

Founders with deep expertise in immunology, drug development, and antibody technology—driven by a shared commitment to patients and science.



CONTACT

terrencew@jeevantx.com

www.jeevantx.com

Jeevan Therapeutics

Lenneuro



Life-Proofing Line Care

SnapCath™ — one device that anchors and covers the catheter site for up to 28 days. Simple, intuitive design for ease of use.

— — —
Steve Scherr, PhD | Co-Founder & CTO, Lenneuro
Steve@Lenneuro.com





Autoimmune patients are trapped on suppression

Systemic	Broad suppression of immune system
At Risk	Serious Infections, Cancer, and Death
Trapped	NO PATH OFF LIFELONG TREATMENT



\$250B global market by 2035

Multiple Sclerosis (MS)



Lead	1.0 M MS Patients in US
Value	>\$85k/yr for DMT
SoC	\$5B-\$7B, LoE 2030+



\$2.5M pre-seed SAFE for *in vivo* PoC

SRA	\$500K Top 10 Pharma MS <i>in vivo</i> PoC
SBIR	\$350K NIGMS Phase I Internal Pipeline



Retrain immune system with mRNA for *tolerance*

- Payload restricted to anti-inflammatory APCs
- **Controller operates at the protein level**



Validated business model (M&A)

Asset	Advance to Clinical Dev.
Revenue	Indication-Specific Licenses
Exit	Patent cliff drives Acquisition

ORNA®



Academic invention plus industry drugmaking

Russ Ernst	CEO 2 assets in clin. dev.
Alex Marzilli	CSO Invented platform
John Ngo	Scientific Co-Founder, BU





AI-Powered Ophthalmology

Too many patients, not enough ophthalmologists.

MyEyesAI enables AI-assisted tele-ophthalmology to expand specialist capacity while improving access to eye care.

MARKET TRACTION

-  Emergency Rooms
-  Department of Corrections
-  Senior Care Facilities
-  Primary Care Sites

TELE-OPHTHALMOLOGY



TEAM



Carl Rosen, MA, MD, MPA
Co-founder & Chief Medical Officer
Oculoplastic Surgeon
President of Ophthalmic Associates



Ritu M. Uberoy
Chief AI Officer
Author, BS & MS Degrees in Computer Science
AI Strategist, Host - The Big Unlock Podcast



Rohit Mahajan
Co-founder & CEO
HBS Alumni and Wharton Fellow
Enterprise tech scaling (IBM, Wipro)






AI-POWERED ROBOTIC PLATFORM FOR AUTONOMOUS IMAGING

Self-driving imaging for the beating heart.

Inside a beating heart, ultrasound imaging is still **controlled entirely by hand**. Four degrees of freedom, steered from outside the body, where a millimeter at the handle changes the view inside the heart chamber. It often takes a **second physician** solely to manage the imaging.

■ THE REALITY TODAY



■ HANDS FREE

The robot interprets ultrasound in real time, automatically maintaining the optimal view throughout the procedure

■ ONE OPERATOR

No second physician. No constant verbal coordination. No wet towel holding the imaging device in place.

■ SMARTER OVER TIME

Autonomy ships as software upgrades on the same FDA-cleared robot.



The future of interventional imaging is **hands free**.

Sean Kyne, Co-Founder & CEO

sean@naviamed.com



Tortuosity is the **ENEMY**
Access is everything




Percutaneous Automated Large Bore Carotid Access
Embolic Protection & Closure System (PCAR)




Neck

Fast
Safe
Simple
Reliable

Chris K. Lear, MBA
Chris@neurofine.com
Chief Strategy Officer



Nuroflux – Non-Invasive Cerebral Blood Flow Monitoring in Stroke Patients



No viable mechanism for continuous monitoring of stroke patients –
neurological deterioration events missed.

Nuroflux developed a **non-invasive wearable** for continuous monitoring of cerebral blood flow, enabling **treatment response monitoring and real-time detection of deterioration.**

1st in-class Antibody Therapeutic

- Cell free DNA (cfDNA) is a universal biomarker
- Forms immune-complexes and causes inflammation
- Anti-DNA antibodies enhance detection & neutralize pathology [Science 383, (2024)]



Parasailllc@gmail.com

Demand_{FC} is the only clinic-ready
anti-DNA antibody



hu3E10 IgG1



Novel therapeutic with paired / commercial
biomarker readout (ie Nextgen DNA Seq)

Partnering Opportunity

- Parasail is a single-member LLC
 - 100% owned by scientific founder
 - Dustin.Armstrong@parasailllc.com
- Over \$60M invested (non-dilutive)
- Treating patients with growing pipeline
 - Demand_{FC} monotherapy (IND-ready)
 - Rare-disease; Enzyme-fusions (Phase I/II)
 - Novel Oligo-delivery platform w/ non-human primate data

Functional, Integrative, and Longevity Medicine (\$66B industry)

The fastest-growing segment of outpatient healthcare has a problem.



We've operated successful practices, partnered with hundreds of providers, and built mission-critical technology at scale.

Contact: Alan Forbes, Alan@ProgressHealthSystems.com



Prometheus Therapeutics

Ajay K. Wakhloo, MD PhD FAHA FSNIS
CEO
Ajay@prometheustherapeutics.com
<https://www.prometheustherapeutics.com>

A Revolutionary Biological Treatment to CURE Aneurysms

Fast

Safe

Simple


Universal

Single Treatment


Pre-Treatment



Bio-Activation



Cure





**SLBST
Pharma**


EFFECTIVELY MANAGING ENDOMETRIOSIS PAIN

Mark Connell
CEO & Co-Founder

mark.connell@slbstpharma.com
(617) 935-5381



A Perfect Fit for Every Heart



Personalized cardiac implants for stroke prevention

Connor Verheyen, PhD
Co-Founder and CEO
connor@sphericbio.com



1

Draw

into a standard collection tube

2

Connect

tube into the SpotOnMe device;
passive separation begins

3

Remove

plasma-ready output tube in ~10
minutes

Diagnostics · Drug Trials · Biotech & Research

Wherever the blood is drawn

A Sample Preparation Platform for Plasma and Serum

- Single tube and high-throughput formats
- No centrifuge, No Electricity, No new tubes
- Three Steps. Ten Minutes. No Equipment.

*Diagnostics going where the **care happens***

rodrigo@spotonmenow.com

Unlocking a New Axis of Metabolic Control

Liam Driscoll-Casey


Liam.Casey@tufts.edu



TETRAXIS
THERAPEUTICS

90% OF DRUGS FAIL
Too manual · too much data

The Right Drug Target, Decided with Certainty.





A Gait Lab Under Your Feet = Movement Intelligence

AI-driven smart insole, app, and clinician dashboard turning everyday steps into performance, recovery, and fall-risk data.

$r > 0.95$ correlation vs.
gold-standard motion capture

Peer-reviewed · Published in ACM IMWUT, March 2026 (UMass Amherst) · 1,200+ gait cycles, 14 participants

SIGNING GTM PARTNERS



Sports Performance

Orthotics

Ted Finn — 4X Founder · 50M+ pairs of shoes & insoles sold

ted@iws4u.com · www.wellssole.co

Now Raising — GTM Round



Live Demo — Ask to See Them



Wicked Smart Pad®

Washable, Sensorized Bedding for Smart Incontinence Care

powered by

WICKED TECHNOLOGIES



Alli Truttmann

CEO & Founder
Wicked Technologies



(618) 531-5284



www.wickedsmartpad.com



alli@wickedsmartteam.com






Zephyr Apnea Technologies

Zephyr Smart Patch™

Non-invasive, AI-enabled, closed-loop therapy for obstructive sleep apnea

Zephyr Platform: sense → predict → stimulate → monitor → optimize



A comfortable wearable therapy designed for home use and adherence

30M

U.S. adults with OSA

<20%

Currently diagnosed

<50%

CPAP adherence

\$3B

CPAP-intolerant beachhead

55

Patent protection

Investment Thesis

Core idea

Comfortable, convenient smart patch that detects, predicts, treats, and monitors OSA at home

Opportunity

OSA care has an access and adherence gap: 30M U.S. adults, <20% diagnosed, <50% CPAP adherence

Differentiator

Beyond CPAP or diagnostics: sensing + AI prediction + adaptive stimulation + connected care in 1 wearable

Traction

55-patent IP portfolio; MIT-rooted team; De Novo path; \$3B CPAP-intolerant beachhead

The ask

Raising \$5M to finalize design, run pilot, and prepare pivotal/FDA submission



Lightning Pitch **Companies**

[1612Bio](#) **Kamran Rizzolo**, Founder & CEO krizzolo@1612bio.com

[Alpha Cure Therapeutics](#) **Scott Cohen**, CEO scottcohen@alphacuretx.com

[AltrixBio](#) **David Pass**, CEO davidpass@altrixbio.com

[AsparaGlue](#) **Paul Birkmeyer**, CEO pbirkmeyer@asparaglu.com

[CPR Therapeutics](#) **Norman Paradis**, CEO norman@cprtherapeutics.com

Entero Devices **Rob Mulligan**, Business & IP Strategy rmulligan@starsidecap.com

[EpiWatch](#) **Teresa Prego**, CEO tprego@epiwatch.com

[EyeJets](#) **David Potter**, Advisor dpotter@sagepartners.net

[Eyevara](#) **Dr. Rae Huang**, OD MS IACMM, CEO drhuang@outlook.com

[FlexiGrace Bio](#) **Arun Singh**, CEO & Founder arun.singh@flexigrace.bio

[GMB Solutions](#) **Daniel Schoener**, CEO daniel@greenmountainbiotechsolutions.com

[Highland Instruments](#) **Alex Herzlinger**, CBO alex@highlandinstruments.com

[Jeevan Therapeutics](#) **Terrence West**, CEO terrencew@jeevantx.com

[Lenneuro](#) **Steven Scherr**, CTO steve@lenneuro.com

[MotiveTx](#) **Russ Ernst**, Co-Founder & CEO russ@motivetherapeutics.bio

[MyEyesAI](#) **Rohit Mahajan**, CEO rohit@myeyesai.com

[Navia Medical](#) **Sean Kyne**, Founder & CEO sean@naviamed.com

[Neurofine](#) **Christopher Lear**, Chief Strategy Officer chris@neurofine.com

[Nuroflux](#) **David Cardoso**, Co-Founder & CBO david.cardoso@nuroflux.com

[Parasail](#) **Dustin Armstrong**, President dustin.armstrong@parasailllc.com

[Progress Health Systems](#) **Alan Forbes**, Co-Founder, CEO Alan@Progresshealthsystems.com

[Prometheus Therapeutics](#) **Ajay Wakhloo**, CEO ajay@prometheustherapeutics.com

[SLBST Pharma](#) **Mark Connell**, Co-Founder & CEO mark.connell@slbstpharma.com

[Spheric Bio](#) **Connor Verheyen**, Co-Founder & CEO connor@sphericbio.com

[SpotOnMe](#) **Rodrigo Navarro**, COO rodrigo@spotonmenow.com

Tetraxis Therapeutics **Liam Casey**, CEO liam.casey@tufts.edu

[WeDaita](#) **Wenliang Zhang**, Founder & CEO wenliang.zhang@wedaita.com

[WellSole](#) **Ted Finn**, Founder ted@iws4u.com

[Wicked Technologies](#) **Alli Truttmann**, Founder & CEO alli@wickedsheets.com

[Zephyr Apnea](#) **Theresa Mock**, COO terri@zephyrapnea.com



Executive Roundtable, MORSE – Third Wednesday of the Month

Sep 3 Angel and Family Office Investing in Healthcare

John Hession, Moderator

John Hallinan

John Parker, Springhood Ventures & Charles Hood Foundation

Josko Silobrcic, Hub Angels

Oct 5 AI – Productivity Improvements and Implementation

Oct 27 Inaugural NorthEast Healthcare Executive Network NYC

Nov 2 Directors and Officers

Dec 7 Year in Review: IPO, M&A, PE & Venture



Idea. Innovation. Transformation.

